ObjectiveGI, the integrated research and technology services platform company, announced its 10th “Center of Research Excellence.” ObjectiveGI is a physician-partnered model that integrates gastroenterology (GI) research services into local practices, providing clinical research as a management option for specialists in support of patient care and practice enhancement. With this 10th center, the company is now partnering with more than 100 GI physicians across the country.
“It’s an exciting time to be in healthcare and support science at the point of care,” says Colleen Hoke, president and CEO, ObjectiveGI. “By partnering with leading GI physicians to create cutting-edge programs, we’re working together to provide the necessary data aimed at developing new NASH therapies and, ultimately, improving patient outcomes.”
Since launching the first “Center of Research Excellence” in 2018, ObjectiveGI and its partners have supported value-based care initiatives for more than 3,000 patients. Today, these centers can be found on-site at GI practices located in Alabama, Arkansas, Florida, Maryland, Michigan, North Carolina, South Carolina and Tennessee. Looking forward, ObjectiveGI plans to double the number of “Center of Excellence” sites by the end of 2020, expanding its transformative presence while driving meaningful partnerships and improved patient outcomes.
“We will continue to add value for all stakeholders and advance emerging care solutions for patients through each one of our research partnerships,” says Dr. Don Lazas, chief medical officer, ObjectiveGI. “Aligning incentives for research sponsors and payers, while providing a premier research infrastructure that allows for GI providers to conduct pivotal clinical trials within the workflow of their practices, remains at the forefront of the work with our physician partners.”
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.